Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
On November 28, 2022, BetterInvesting Magazine announced Icon PLC (NYSE: ICLR) as its "Stock to Study" and Williams-Sonoma Inc. (NYSE: WSM) as its "Undervalued Stock" for the January-February 2023 issue. The initiative is aimed at enhancing investors' financial literacy and empowering informed investment decisions. BetterInvesting encourages potential investors to conduct thorough reviews using their online tools. The recommendations serve purely educational purposes and do not constitute endorsements for purchase.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Evercore ISI HealthCONx Conference on November 30, 2022, at 08:00 am EST. The presentation will be available via live webcast. For updates and links to the webcast, visit the Investor section of ICON's website under 'Events'. As of September 30, 2022, ICON employed around 41,150 people across 113 locations in 53 countries, enhancing clinical research and patient care.
ICON plc (NASDAQ: ICLR) reported third quarter 2022 results showcasing strong financial performance. Net business wins reached $2,351 million, with a book-to-bill ratio of 1.21. Revenue for Q3 was $1,942.4 million, up 3.9% year-on-year. Year-to-date revenue hit $5,779.4 million, reflecting a 60.6% increase. Adjusted EBITDA stood at $379.6 million, representing 19.5% of revenue. Adjusted net income was $247.2 million, leading to $3.00$7,690 - $7,810 million.
ICON plc (NASDAQ: ICLR) has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial for the AV7909 anthrax vaccine. Funded by BARDA, this trial aims to evaluate the immune response of healthy adults to the next-generation vaccine, with activities including project management and clinical operations. ICON has significant experience in vaccine studies, participating in over 160 trials in the past five years. The trial will start in early 2023, addressing the potential threat of anthrax exposure.
ICON plc (NASDAQ: ICLR) will release its Q3 2022 financial results on November 2, 2022, post market close. A conference call will follow on November 3, 2022, at 8:00 AM ET to discuss the results. As of June 30, 2022, ICON employed approximately 40,500 staff across 119 locations in 53 countries. The firm emphasizes its role in advancing clinical research and patient care, but noted that forward-looking statements are subject to risks that could affect actual results. Further updates will be provided on the Investor Relations section of the ICON website.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 10:25 AM EDT. The presentation will be accessible via a live webcast, with any updates available on their investor website under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 40,500 individuals across 119 locations in 53 countries as of June 30, 2022.
ICON plc (NASDAQ: ICLR) announced that all resolutions during its Annual General Meeting on July 26, 2022, were approved by shareholders. Key resolutions included the re-election of directors and the authorization to allot shares. Major retirements from the Board were noted, including Professor William Hall and Ms. Mary Pendergast, who have served since 2013 and 2014, respectively. The meeting reflects ICON's commitment to governance and shareholder engagement, with approximately 68.8 million votes cast on various resolutions, affirming shareholder confidence.
ICON plc (NASDAQ: ICLR) reported strong Q2 2022 results with net business wins of $2,323 million and a book-to-bill ratio of 1.20. Revenue reached $1,935.2 million, up 122.1% year-over-year. Adjusted EBITDA stood at $354.3 million, 18.3% of revenue, reflecting a yearly increase of 120.2%. Adjusted net income was $235.8 million, with earnings per share of $2.86. The company revised its full year 2022 revenue guidance to $7,690 - $7,810 million, anticipating a 40.3% to 42.5% increase year-over-year.
ICON, a leading healthcare intelligence and clinical research organization (NASDAQ: ICLR), will release its financial results for Q2 2022 on July 27, 2022, after market close. A conference call to discuss these results is scheduled for July 28, 2022, at 8:00am ET. This announcement underscores ICON's dedication to transparency and investor communication. As of March 31, 2022, ICON employed approximately 39,300 individuals across 138 locations globally, emphasizing its expansive operational capacity.
FAQ
What is the current stock price of ICON PLC (ICLR)?
What is the market cap of ICON PLC (ICLR)?
